

## Newsletter for Participants, their Friends and Families

We would like to say a huge thank you to all the patients, their supportive families and carers from across the UK who have taken part in the SCOPE2 trial. This newsletter gives you an update on how the trial is progressing.

SCOPE2 is still recruiting patients and now has over 380 participants, making it the biggest trial in the world for this type of disease. The trial is expected to close to recruitment at the end of 2023. After this time we will continue to collect data from follow up visits for the next two years, with an aim to analyse the data and publish the trial results in 2026. We should then have an answer to the question of whether a higher radiotherapy dose can improve the treatment of oesophageal cancer. You will be able to access any publications and study results with the help of your study team. Your confidential information will **not** appear in any of the results or publications.

Your support over the last few years has been phenomenal, and we are so grateful for your contribution towards finding the best treatment for you and other patients in the future. We hope that the visits, questionnaires and tests have not been too demanding. Your contribution continues to be incredibly valuable and we will learn a lot from the results.

### Safety of SCOPE2

The data from the study is reviewed every 6 to 12 months by an Independent Data Monitoring Committee to make sure that all the patients are safe. The committee had their last meeting in February 2023 and they were satisfied with the quality of the study and the safety of SCOPE2.

### The SCOPE2 Qualitative Interview Study

Thank you to those SCOPE2 patients who agreed to be interviewed about their experience on the trial for a separate interview study. These interviews have given us a deeper insight and understanding about what it is like to be a participant in SCOPE2 and receive the trial treatment. This interview study is now closed and the results will be published soon.

### PET sub-study results

We now have the results of the PET sub study where a group of SCOPE2 participants received an extra PET scan 14 days after the start of treatment. If the PET scan didn't show that the chemotherapy was shrinking the tumour then half of these patients were switched to different chemotherapy drugs.

An independent review of the data showed that changing chemotherapy was not any better for patients than staying on the same chemotherapy for the rest of their treatment. It was therefore decided to stop this part of the trial. SCOPE2 is continuing to recruit patients in order to answer our other questions.

Thank you to those SCOPE2 patients who took part in this sub study. We wouldn't have the answer to this question without your help!

